Neuroblastoma Paradigm for Precision Medicine

被引：253

作者：

Irwin, Meredith S. ^{[1
]}

Park, Julie R. ^{[2
]}

机构：

[1] Univ Toronto, Hosp Sick Children, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada

[2] Univ Washington, Div Hematol Oncol, Seattle Childrens Hosp, Sch Med,Fred Hutchinson Canc Res Ctr, Seattle, WA 98105 USA

来源：

PEDIATRIC CLINICS OF NORTH AMERICA | 2015年 / 62卷 / 01期

关键词：

Neuroblastoma; Risk stratification; MYCN; Segmental chromosome aberrations (SCA); ALK (anaplastic lymphoma kinase); Phox2B; Myeloablative therapy (MAT); Immunotherapy; HIGH-RISK NEUROBLASTOMA; STAGE; 4; NEUROBLASTOMA; STEM-CELL TRANSPLANTATION; TUMOR-SUPPRESSOR GENE; EXPRESSION-BASED CLASSIFICATION; REFRACTORY SOLID TUMORS; CENTRAL-NERVOUS-SYSTEM; HIGH-DOSE CHEMOTHERAPY; IV-S NEUROBLASTOMA; LONG-TERM OUTCOMES;

D O I：

10.1016/j.pcl.2014.09.015

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Neuroblastoma (NB) is the third most common pediatric cancer. Although NB accounts for 7% of pediatric malignancies, it is responsible for more than 10% of childhood cancer-related mortality. Prognosis and treatment are determined by clinical and biological risk factors. Estimated 5-year survival rates for patients with non-high-risk and high-risk NB are more than 90% and less than 50%, respectively. Recent clinical trials have continued to reduce therapy for patients with non-high-risk NB, including the most favorable subsets who are often followed with observation approaches. In contrast, high-risk patients are treated aggressively with chemotherapy, radiation, surgery, and myeloablative and immunotherapies.

引用

页码：225 / +

页数：33

共 220 条

[1] Efficacy of complete resection for high-risk neuroblastoma: A children's cancer group study [J].

Adkins, ES ;

Sawin, R ;

Gerbing, RB ;

London, WB ;

Matthay, KK ;

Haase, GM .

JOURNAL OF PEDIATRIC SURGERY, 2004, 39 (06) :931-936

[2] Natural history and biology of Stage A neuroblastoma: A Pediatric Oncology Group study [J].

Alvarado, CS ;

London, WB ;

Look, AT ;

Brodeur, GM ;

Altmiller, DH ;

Thorner, PS ;

Joshi, VV ;

Rowe, ST ;

Nash, MB ;

Smith, EI ;

Castleberry, RP ;

Cohn, SL .

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2000, 22 (03) :197-205

[3] International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee [J].

Ambros, P. F. ;

Ambros, I. M. ;

Brodeur, G. M. ;

Haber, M. ;

Khan, J. ;

Nakagawara, A. ;

Schleiermacher, G. ;

Speleman, F. ;

Spitz, R. ;

London, W. B. ;

Cohn, S. L. ;

Pearson, A. D. J. ;

Maris, J. M. .

BRITISH JOURNAL OF CANCER, 2009, 100 (09) :1471-1482

[4]

Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330

[5] Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma [J].

Asgharzadeh, Shahab ;

Salo, Jill A. ;

Ji, Lingyun ;

Oberthuer, Andre ;

Fischer, Matthias ;

Berthold, Frank ;

Hadjidaniel, Michael ;

Liu, Cathy Wei-Yao ;

Metelitsa, Leonid S. ;

Pique-Regi, Roger ;

Wakamatsu, Peter ;

Villablanca, Judith G. ;

Kreissman, Susan G. ;

Matthay, Katherine K. ;

Shimada, Hiroyuki ;

London, Wendy B. ;

Sposto, Richard ;

Seeger, Robert C. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) :3525-3532

[6] RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours [J].

Astuti, D ;

Agathanggelou, A ;

Honorio, S ;

Dallol, A ;

Martinsson, T ;

Kogner, P ;

Cummins, C ;

Neumann, HPH ;

Voutilainen, R ;

Dahia, P ;

Eng, C ;

Maher, ER ;

Latif, F .

ONCOGENE, 2001, 20 (51) :7573-7577

[7] Chromosome 1p and 11q deletions and outcome in neuroblastoma [J].

Attiyeh, EF ;

London, WB ;

Mossé, YP ;

Wang, Q ;

Winter, C ;

Khazi, D ;

McGrady, PW ;

Seeger, RC ;

Look, AT ;

Shimada, H ;

Brodeur, GM ;

Cohn, SL ;

Matthay, KK ;

Maris, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (21) :2243-2253

[8] Significance of MYCN Amplification in International Neuroblastoma Staging System Stage 1 and 2 Neuroblastoma: A Report From the International Neuroblastoma Risk Group Database [J].

Bagatell, Rochelle ;

Beck-Popovic, Maja ;

London, Wendy B. ;

Zhang, Yang ;

Pearson, Andrew D. J. ;

Matthay, Katherine K. ;

Monclair, Tom ;

Ambros, Peter F. ;

Cohn, Susan L. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) :365-370

[9] Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma. [J].

Baker, David L. ;

Schmidt, Mary L. ;

Cohn, Susan L. ;

Maris, John M. ;

London, Wendy B. ;

Buxton, Allen ;

Stram, Daniel ;

Castleberry, Robert P. ;

Shimada, Hiroyuki ;

Sandler, Anthony ;

Shamberger, Robert C. ;

Look, A. Thomas ;

Reynolds, C. Patrick ;

Seeger, Robert C. ;

Matthay, Katherine K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (14) :1313-1323

[10] MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance [J].

Barone, Giuseppe ;

Tweddle, Deborah A. ;

Shohet, Jason M. ;

Chesler, Louis ;

Moreno, Lucas ;

Pearson, Andrew D. J. ;

Van Maerken, Tom .

CURRENT DRUG TARGETS, 2014, 15 (01) :114-123

← 1 2 3 4 5 6 7 8 9 10 →